

































- guidelines. *Circulation*, 143(5):e72-e227. <https://doi.org/10.1161/CIR.0000000000000923>
- Radhoe SP, Veenis JF, Van Mieghem NM, et al., 2021. The effect of transcatheter aortic valve implantation on pulmonary artery pressures in a patient suffering from chronic heart failure: A case report. *Eur Heart J Case Rep*, 5(4):ytab112. <https://doi.org/10.1093/ehjcr/ytab112>
- Sato K, Kumar A, Krishnaswamy A, et al., 2019. B-type natriuretic peptide is associated with remodeling and exercise capacity after transcatheter aortic valve replacement for aortic stenosis. *Clin Cardiol*, 42(2):270-276. <https://doi.org/10.1002/clc.23138>
- Schewel J, Schmidt T, Kuck KH, et al., 2019. Impact of pulmonary hypertension hemodynamic status on long-term outcome after transcatheter aortic valve replacement. *JACC Cardiovasc Interv*, 12(21):2155-2168. <https://doi.org/10.1016/j.jcin.2019.08.031>
- Sigvardsen PE, Larsen LH, Carstensen HG, et al., 2017. Six-minute walking test and long term prognosis in patients with asymptomatic aortic valve stenosis. *Int J Cardiol*, 249:334-339. <https://doi.org/10.1016/j.ijcard.2017.09.183>
- Simonneau G, Montani D, Celermajer DS, et al., 2019. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*, 53(1) <https://doi.org/10.1183/13993003.01913-2018>
- Stubbs H, Lua S, Brewis M, et al., 2022. Compera 2.0 risk stratification in medically managed chronic thromboembolic pulmonary hypertension. *Eur Respir J*, 60(3) <https://doi.org/10.1183/13993003.00313-2022>
- Thyregod HGH, Ihlemann N, Jorgensen TH, et al., 2019. Five-year clinical and echocardiographic outcomes from the nordic aortic valve intervention (notion) randomized clinical trial in lower surgical risk patients. *Circulation*, <https://doi.org/10.1161/CIRCULATIONAHA.118.036606>
- Tuttle MK, Kiaii B, Van Mieghem NM, et al., 2022. Functional status after transcatheter and surgical aortic valve replacement: 2-year analysis from the surtavi trial. *JACC Cardiovasc Interv*, 15(7):728-738. <https://doi.org/10.1016/j.jcin.2022.01.284>
- Vachieri JL, Tedford RJ, Rosenkranz S, et al., 2019. Pulmonary hypertension due to left heart disease. *Eur Respir J*, 53(1) <https://doi.org/10.1183/13993003.01897-2018>
- Vahanian A, Beyersdorf F, Praz F, et al., 2022. 2021 esc/eacts guidelines for the management of valvular heart disease. *Eur Heart J*, 43(7):561-632. <https://doi.org/10.1093/eurheartj/ehab397>
- Writing Committee M, Otto CM, Nishimura RA, et al., 2020. 2020 acc/aaha guideline for the management of patients with valvular heart disease: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. *J Am Coll Cardiol*, 77(4):e25-e197. <https://doi.org/10.1016/j.jacc.2020.11.018>
- Xu H, Liu Q, Cao K, et al., 2022. Distribution, characteristics, and management of older patients with valvular heart disease in china. *JACC: Asia*, 2(3):354-365. <https://doi.org/10.1016/j.jacasi.2021.11.013>